Aptose Biosciences

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held in-person and virtually September 12-14, 2022, in New York City.

Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO Fletcher Payne - SVP and Chief Financial Officer Rafael Bejar - SVP and Chief Medical Officer Conference Call Participants Matthew Biegler - Oppenheimer Li Watsek - Cantor Fitzgerald Edward Tenthoff - Piper Sandler Soumit Roy - Jones Trading John Newman - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the Aptose Biosciences Inc. Reports Result for the Second Quarter 2022.

Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2022 Results - Earnings Call Transcript

─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─

Aptose Reports Results for the Second Quarter 2022

SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, and Mr. Fletcher Payne, CFO of Aptose, will attend the Canaccord Genuity 42nd Annual Growth Conference, and Dr. Rice will present at the Conference:

Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pave the way toward registration studies, and dose escalation studies of the new luxeptinib formulation could begin in early 2023.

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended June 30, 2022, on Tuesday, August 2, 2022 after the close of the market, and provide a corporate update.

Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the position of Senior Vice President, Chief Financial Officer (CFO). In this role, Mr. Payne will lead Aptose's financial operations and serve as a member of the Company's executive management team.

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

Aptose Presents Highlights from Corporate Update and KOL Event

SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, May 31, 2022 (the “Meeting”). A total of 53.46% of the common shares of the Company entitled to be voted were represented by shareholders present or represented by proxy at the Meeting.

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Clinical Updates for HM43239 and Luxeptinib

Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dr. William G. Rice – Chairman, President and Chief Executive Officer Dr. Rafael Bejar – Senior Vice President and Chief Medical Officer Dan Ferry – Managing Director, LifeSci Advisors LLC Conference Call Participants Gregory Renza – RBC Capital Markets Matthew Biegler – Oppenheimer & Co. Inc. Li Watsek – Cantor Fitzgerald Matthew Cross – Allegiance Global Partners Operator Welcome to the Aptose Biosciences o Incorporated Reports Result for the First Quarter 2022 Conference Call.

Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results - Earnings Call Transcript

Aptose Reports Results for the First Quarter 2022

SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. Currently, an international Phase 1/2 clinical trial is ongoing for HM43239 in the R/R AML patient population. HM43239 received orphan drug designation from the FDA for treatment of acute myeloid leukemia in 2018.

Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, will participate in the RBC Capital Markets Global Healthcare Conference:

Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference

Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended March 31, 2022, on Monday, May 9, 2022 after the close of the market, and provide a corporate update.

Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022

─ Appoints Philippe Ledru as Chief Commercial Officer ─

Aptose Announces Executive Management Changes

SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel to discuss new approaches of treating acute myeloid leukemias (AML) at Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference:

Aptose to Present at Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference

Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q4 2021 Results - Earnings Call Transcript

- HM43239 clinical remission at 120mg expands list of potential treatable AML populations -

Aptose Reports Results for the Fourth Quarter and Full Year 2021

SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and quarter ended December 31, 2021, on Tuesday, March 22, 2022 after the close of the market, and provide a corporate update.

Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer's 32nd Annual Healthcare Conference:

Aptose to Present at Oppenheimer's 32nd Annual Healthcare Conference

Celularity

CNS Pharmaceuticals

Celyad

Spruce Biosciences

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

5 Beaten-Down Biotech Bets to Bounce Back in 2022

— H.C. Wainwright BIOCONNECT Virtual Conference —

News for Aptose Biosciences Stock (APTO)